Skip to main content
. Author manuscript; available in PMC: 2020 Jun 30.
Published in final edited form as: Clin Cancer Res. 2018 Mar 7;24(11):2585–2593. doi: 10.1158/1078-0432.CCR-17-3811

Figure 6.

Figure 6.

Efficacy of SN38-TOA nanoparticles (NP) on IMR-32 flank xenografts. A, Tumor growth inhibition by SN38-TOA. IMR-32 cells were implanted subcutaneously in the flank of each mouse. Mice (n = 4/arm) were treated intravenously via tail vein injections with SN38-TOA nanoparticles (10 mg/kg) twice per week for 4 weeks when tumors reached a volume of 1.5 cm3. B, Event-free survival curves of CPT-11–re-treated mice. Mice were removed from the study when the tumor volumes reached 3.0 cm3. SN38-TOA nanoparticles caused the tumors to completely regress in all of the mice (P = 0.0101).